Physician profile
Naval H Patel
NPI 1760826887
$1,409.73
in general payments reported to CMS, 2019-2025
25 companies · $653 in 2025
The $653 reported for 2025 was more than what 79% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $14.86 · 2022: $26.58 · 2023: $201 · 2024: $178 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wright Medical Technology, INC. | $336.20 | 2019 | |
| Ucb, INC. | $200.30 | 2024-2025 | Rystiggo |
| Csl Behring | $184.72 | 2025 | Hizentra |
| Springworks Therapeutics, INC. | $124.92 | 2025 | Gomekli |
| Treace Medical Concepts, INC. | $58.33 | 2023 | |
| Averitas Pharma INC. | $46.12 | 2024 | Qutenza |
| Polynovo North America LLC | $45.09 | 2023-2025 | Novosorb Btm |
| Mallinckrodt Hospital Products INC. | $43.08 | 2024-2025 | Acthar |
| Shield Therapeutics INC | $38.92 | 2023 | Accrufer |
| Paratek Pharmaceuticals, INC. | $37.46 | 2023 | Nuzyra |
| Globus Medical, INC. | $31.67 | 2025 | Senza |
| Merz Pharmaceuticals, LLC | $30.08 | 2025 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.26 | 2023 | Jublia |
| Lundbeck LLC | $25.10 | 2025 | Vyepti |
| Tg Therapeutics, INC. | $20.25 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.08 | 2025 | Ultomiris |
| Biogen, INC. | $18.99 | 2024 | Skyclarys |
| Smith+Nephew, INC. | $16.92 | 2024 | Stravix, Grafix Pl |
| Takeda Pharmaceuticals U.S.A., INC. | $16.86 | 2025 | Hyqvia |
| Pfizer INC. | $16.52 | 2024 | |
| Ns Pharma, INC. | $15.90 | 2025 | Viltepso |
| Glaxosmithkline, LLC. | $15.52 | 2023 | Arexvy, Shingrix |
| Stryker Corporation | $14.90 | 2022 | |
| Zyla Life Sciences, INC. | $14.86 | 2020 | |
| Zimvie INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naval Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.